Use of a NAT-based assay to improve the surveillance system and prevent transfusion-transmitted malaria in blood banks

Table 1 Demographic and clinical characteristics of FMT–HVD patient samples used for validation of the HIV/HCV/HBV/Malaria NAT assay

Patient	Source	Gender	Age	Parasitaemia (parasites/µL)		Asexual parasitaemia (parasites/µL)
Patient	Source	Gender	Age	Asexual	Sexual	Rings	Trophozoites	Schizonts
1	FMT–HVD	F	26	5757.6	242.4	666.6	5091	0
2	FMT–HVD	M	43	5355.2	644.8	2221	3080.6	53.7
3	FMT–HVD	M	35	6000	0	3060	2940	0
4	FMT–HVD	M	21	6100	0	3468	2632.3	0
5	FMT–HVD	M	37	5861.7	138.3	1078	4783.4	0
6	FMT–HVD	M	20	5847.6	152.4	4476	1352.4	19
7	FMT–HVD	M	35	6000	0	5040	960	0
8	FMT–HVD	F	40	6000	0	0	6000	0
9	FMT–HVD	M	29	5841.7	158.3	1285	4504.4	52.8
10	FMT–HVD	F	32	6000	0	0	6000	0
11	FMT–HVD	M	49	6000	0	4254	1746.5	0
12	FMT–HVD	M	36	4610.7	1389.3	3785	805.4	20.1
13	FMT–HVD	M	17	6000	0	5345	655.2	0
14	FMT–HVD	F	21	6000	0	3558	2441.9	0
15	FMT–HVD	F	34	6000	0	1774	4226.1	0
16	FMT–HVD	M	34	5613.4	386.6	2799	2814.4	0

ISSN: 1475-2875